55 related articles for article (PubMed ID: 21448425)
1. Loss of α-1,2-mannosidase MAN1C1 promotes tumorigenesis of intrahepatic cholangiocarcinoma through enhancing CD133-FIP200 interaction.
Wei Y; Chen Q; Chen J; Zhou C; Geng S; Shi D; Huang S; Liang Z; Chen X; Ren N; Jiang J
Cell Rep; 2023 Dec; 42(12):113588. PubMed ID: 38117655
[TBL] [Abstract][Full Text] [Related]
2. Advances of cancer-associated fibroblasts in liver cancer.
Peng H; Zhu E; Zhang Y
Biomark Res; 2022 Aug; 10(1):59. PubMed ID: 35971182
[TBL] [Abstract][Full Text] [Related]
3. Comparison of growth features and cancer stem cell prevalence in intrahepatic and extrahepatic cholangiocarcinoma cell lines.
Yang J; Sontag DP; Burczynski FJ; Xi S; Gong Y; Minuk GY
Clin Exp Hepatol; 2022 Mar; 8(1):60-69. PubMed ID: 35415255
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of T cells secreting αCD133-αCD3 bispecific T-cell engager against cholangiocarcinoma.
Sangsuwannukul T; Supimon K; Chieochansin T; Choomee K; Sujjitjoon J; Junking M; Yenchitsomanus PT
PLoS One; 2022; 17(3):e0265773. PubMed ID: 35312724
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic Inheritance From Normal Origin Cells Can Determine the Aggressive Biology of Tumor-Initiating Cells and Tumor Heterogeneity.
Feng J; Zhao D; Lv F; Yuan Z
Cancer Control; 2022; 29():10732748221078160. PubMed ID: 35213254
[TBL] [Abstract][Full Text] [Related]
6. A simple scoring system to predict early recurrence of Bismuth-Corlette type IV perihilar cholangiocarcinoma.
Peng DZ; Lu J; Li B; Hu HJ; Ye XW; Xiong XZ; Cheng NS
Gastroenterol Rep (Oxf); 2019 Oct; 7(5):345-353. PubMed ID: 31687154
[TBL] [Abstract][Full Text] [Related]
7. Role of Cancer Stem Cells in Cholangiocarcinoma and Therapeutic Implications.
Wu HJ; Chu PY
Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31450710
[TBL] [Abstract][Full Text] [Related]
8. Cytoplasmic CD133 expression correlates with histologic differentiation and is a significant prognostic factor in extrahepatic bile duct cancer and gallbladder cancer.
Mizukami T; Kamachi H; Mitsuhashi T; Einama T; Hatanaka Y; Kamiyama T; Taketomi A
Oncol Lett; 2018 Nov; 16(5):6423-6430. PubMed ID: 30405779
[TBL] [Abstract][Full Text] [Related]
9. CD133 expression in cancer cells predicts poor prognosis of non-mucin producing intrahepatic cholangiocarcinoma.
Cai X; Li J; Yuan X; Xiao J; Dooley S; Wan X; Weng H; Lu L
J Transl Med; 2018 Mar; 16(1):50. PubMed ID: 29510695
[TBL] [Abstract][Full Text] [Related]
10. New insights into cholangiocarcinoma: multiple stems and related cell lineages of origin.
Bragazzi MC; Ridola L; Safarikia S; Matteo SD; Costantini D; Nevi L; Cardinale V
Ann Gastroenterol; 2018; 31(1):42-55. PubMed ID: 29333066
[TBL] [Abstract][Full Text] [Related]
11. Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma.
Feng KC; Guo YL; Liu Y; Dai HR; Wang Y; Lv HY; Huang JH; Yang QM; Han WD
J Hematol Oncol; 2017 Jan; 10(1):4. PubMed ID: 28057014
[TBL] [Abstract][Full Text] [Related]
12. Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA).
Banales JM; Cardinale V; Carpino G; Marzioni M; Andersen JB; Invernizzi P; Lind GE; Folseraas T; Forbes SJ; Fouassier L; Geier A; Calvisi DF; Mertens JC; Trauner M; Benedetti A; Maroni L; Vaquero J; Macias RI; Raggi C; Perugorria MJ; Gaudio E; Boberg KM; Marin JJ; Alvaro D
Nat Rev Gastroenterol Hepatol; 2016 May; 13(5):261-80. PubMed ID: 27095655
[TBL] [Abstract][Full Text] [Related]
13. Downregulated expression of PHLDA1 protein is associated with a malignant phenotype of cholangiocarcinoma.
Zhao PO; Li X; Lu Y; Liu L
Oncol Lett; 2015 Aug; 10(2):895-900. PubMed ID: 26622591
[TBL] [Abstract][Full Text] [Related]
14. Profiles of cancer stem cell subpopulations in cholangiocarcinomas.
Cardinale V; Renzi A; Carpino G; Torrice A; Bragazzi MC; Giuliante F; DeRose AM; Fraveto A; Onori P; Napoletano C; Franchitto A; Cantafora A; Grazi G; Caporaso N; D'Argenio G; Alpini G; Reid LM; Gaudio E; Alvaro D
Am J Pathol; 2015 Jun; 185(6):1724-39. PubMed ID: 25892683
[TBL] [Abstract][Full Text] [Related]
15. Decreased expression of TFPI-2 correlated with increased expression of CD133 in cholangiocarcinoma.
Chu X; Zhao P; Lv Y; Liu L
Int J Clin Exp Pathol; 2015; 8(1):328-36. PubMed ID: 25755719
[TBL] [Abstract][Full Text] [Related]
16. Strong expression of CD133 is associated with increased cholangiocarcinoma progression.
Leelawat K; Thongtawee T; Narong S; Subwongcharoen S; Treepongkaruna SA
World J Gastroenterol; 2011 Mar; 17(9):1192-8. PubMed ID: 21448425
[TBL] [Abstract][Full Text] [Related]
17. Characterization of CD133+ parenchymal cells in the liver: histology and culture.
Yoshikawa S; Zen Y; Fujii T; Sato Y; Ohta T; Aoyagi Y; Nakanuma Y
World J Gastroenterol; 2009 Oct; 15(39):4896-906. PubMed ID: 19842219
[TBL] [Abstract][Full Text] [Related]
18. Expression of CD24 in cholangiocarcinoma cells is associated with disease progression and reduced patient survival.
Keeratichamroen S; Leelawat K; Thongtawee T; Narong S; Aegem U; Tujinda S; Praditphol N; Tohtong R
Int J Oncol; 2011 Oct; 39(4):873-81. PubMed ID: 21687942
[TBL] [Abstract][Full Text] [Related]
19. CD133 expression is a potential prognostic indicator in intrahepatic cholangiocarcinoma.
Shimada M; Sugimoto K; Iwahashi S; Utsunomiya T; Morine Y; Imura S; Ikemoto T
J Gastroenterol; 2010 Aug; 45(8):896-902. PubMed ID: 20379837
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
